The 2026 Nobel Prize in Chemistry was awarded to Henri Kagan and Kensō Soai for their breakthrough in understanding nature’s chemical asymmetry, significantly aiding pharmaceutical manufacturing and other materials. Chiral molecules, which exist in mirror-image forms (like left and right hands), exhibit the peculiar phenomenon of homochirality—living organisms predominantly contain only one form, despite both enantiomers having similar properties but differing behaviors.
This uniqueness complicates drug development; one enantiomer may be therapeutic, while its counterpart produces adverse effects. Historically, attempts to replicate homochirality in the lab struggled, often yielding equal amounts of both forms.
In the early 20th century, chemist Willy Marckwald managed to create an asymmetric reaction, slightly favoring one form using a chiral catalyst. However, the results were modest. Charles Frank, in 1953, outlined conditions for achieving homochirality, particularly emphasizing autocatalysis—a feedback mechanism where a small advantage in one variant accelerates its formation.
Kagan focused on this principle beginning in the early 1980s, improving asymmetric reactions through an intricate understanding of catalysts. Before this, it was thought that equal mixtures of chiral molecules would lead to balanced outcomes, but Kagan’s research challenged this notion, paving the way for more efficient and selective chemical synthesis.
